A long-term clinical study indicates that acting before rheumatoid arthritis fully develops could substantially change its course.
Treating individuals before rheumatoid arthritis (RA) fully sets in may offer something medicine rarely provides: extra time. A new long-term study suggests that for people at high risk, early use of abatacept can delay the onset of the disease for years, with effects that persist even after treatment stops.
Conducted by researchers at King’s College London and published in The Lancet Rheumatology, the study builds on findings from a 2024 trial by the same team.
The original trial followed 213 participants in the UK and the Netherlands over two years. The latest analysis extends that follow-up to four to eight years, making it one of the longest studies focused on individuals at risk of developing RA.
Rheumatoid arthritis (RA) is a long-term autoimmune condition affecting around half a million people in the UK. It arises when the immune system mistakenly targets the joints, causing pain, swelling, fatigue, and lasting disability.
Those at risk frequently exit the workforce even before symptoms appear, adding to financial pressure and wider economic impacts.
Existing Treatment Limitations and New Insights
Although treatments exist for people with established RA, no approved therapy currently prevents the disease in those at risk.
The researchers found that a 12-month course of abatacept produced benefits that extended well beyond the treatment period. Participants who received the drug developed RA significantly later than those given a placebo, with onset delayed by up to four years after treatment ended.
While the therapy did not eliminate RA entirely, the findings suggest that early intervention can reshape the disease’s progression by postponing its onset, potentially reducing the overall duration of symptoms and complications.
Andrew Cope, Professor of Rheumatology at the Centre for Rheumatic Diseases at King’s College London and the study’s lead author, said that acting early in individuals at high risk of RA can deliver lasting benefits. He noted that the approach is safe, can prevent the disease during treatment, and significantly ease symptoms. Crucially, it can also postpone the onset of RA for several years even after therapy ends, potentially shortening the time patients live with symptoms and complications and greatly improving their quality of life.
Which Patients Benefit Most From Treatment
The study showed that abatacept was most effective in people at the highest risk of developing RA, identified through a blood test that detects specific autoantibodies.
Although this group had a greater likelihood of progressing to RA, they also experienced the strongest benefits from early intervention.
While taking the drug, participants reported reduced joint pain and fatigue, along with improved overall wellbeing. However, once treatment ended, symptom levels in both the treatment and placebo groups became similar, suggesting that continued immune modulation may be necessary to sustain symptom relief.
The researchers found that abatacept had a good safety profile, with comparable rates of serious adverse events in both the treatment and placebo groups and no safety issues attributed to the drug.
Overall, the results indicate that early, targeted immune therapy may delay the development of RA in high-risk individuals, reinforcing the need for further research into preventive approaches for autoimmune diseases.
Read the original article on: SciTechDaily
Read more: AI treadmill detects early Alzheimer’s and Parkinson’s signs